Introduction
Ion channels play a crucial role in regulating metabolic processes such as hormone secretion, gut motility, and electrolyte balance. The Metabolic and Gastrointestinal Ion Channel Portfolio focuses on key ion channel targets relevant to these systems: Kv1.3 (Voltage-gated potassium channel): Regulates T-cell activation and insulin secretion, making it a promising target for metabolic disorders, including diabetes and obesity; Kir6.2/SUR1 (ATP-sensitive potassium channel): Essential for pancreatic β-cell insulin secretion, this channel is a critical target for diabetes therapies; CFTR (Cystic Fibrosis Transmembrane Conductance Regulator): Controls chloride ion transport and electrolyte balance, offering therapeutic potential in the treatment of diarrheal diseases and other electrolyte imbalances; TRPV1 (Transient Receptor Potential Vanilloid 1): Involved in pain perception and inflammation, targeting this channel can help manage inflammatory bowel disease (IBD) and other gastrointestinal inflammatory conditions; P2X3 (Purinergic receptor): Plays a key role in sensory signaling related to pain and inflammation, making it a viable target for irritable bowel syndrome (IBS) and inflammatory pain disorders; 5-HT3A (Ionotropic serotonin receptor): Modulates gut motility and secretion, positioning it as a significant target for gastrointestinal disorders such as IBS, nausea, and vomiting.
Metabolic and Gastrointestinal ion channel Portfolio
Our Metabolic and Gastrointestinal portfolio offers a comprehensive off-target profile of the principal ion channels that have an impact on physiological function of metabolic and gastrointestinal system.
The metabolic and gastrointestinal Ion Channel Portfolio focuses on ion channels linked to essential physiological processes such as hormone secretion, gut motility, and electrolyte balance. This panel is designed to assist in the identification of selective targets for therapeutic interventions in metabolic disorders (e.g., diabetes and obesity) and gastrointestinal diseases (e.g.,diarrhea, irritable bowel syndrome, and inflammatory bowel disease).
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.